Skip to main content

Table 3 The clinical and radiomic characteristics of patients in the training and validation cohorts

From: Baseline MRI-based radiomics model assisted predicting disease progression in nasopharyngeal carcinoma patients with complete response after treatment

Characteristic Training cohort(n = 119) Validation cohort(n = 52) P value
Age (mean ± SD, years) 43.34 ± 12.5 44.81 ± 13.1 0.49
Gender 0.44
 Male 95 38  
 Female 24 14  
Histology 0.79
 Differentiated Non-keratinising 62 26  
 Undifferentiated
 Non-keratinising
57 26  
T stage 0.13
 T1 17 6  
 T2 21 10  
 T3 40 26  
 T4 41 10  
N stage 0.11
 N0 10 2  
 N1 41 14  
 N2 53 22  
 N3 15 14  
Overall stage 0.71
 I 1 0  
 II 14 5  
 III 50 19  
 IV 54 28  
Treatment 0.24
 A 14 8  
 B 56 28  
 C 5 5  
 D 44 11  
EA-IgA
 Positive 38 15 0.82
 Negative 81 37  
VCA-IgA
 Positive 42 33 1.00
 Negative 77 19  
Smoking 1.00
 Yes 57 25  
 No 62 27  
Variance_T1 7.67 ± 0.71 7.64 ± 0.70 0.77
IQR_T1 4.34 ± 0.76 4.37 ± 0.69 0.81
Skewness_T2 −1.79 ± 0.70 −1.96 ± 0.72 0.16
Kurtosis_T1H 6.62 ± 2.29 6.71 ± 1.55 0.80
HGLZE_T2H 2.87 ± 0.43 2.92 ± 0.39 0.45
HGLZE_T1 3.03 ± 0.41 3.16 ± 0.42 0.06
DV_T1 22.17 ± 2.16 22.51 ± 2.10 0.34
Kurtosis_T1L 8.24 ± 3.82 7.69 ± 2.92 0.35
LDLGLE_T1 145.67 ± 11.28 147.02 ± 11.15 0.47
Kurtosis_T2 9.04 ± 9.04 8.18 ± 4.83 0.52
HGLZE_T2L 2.55 ± 0.51 2.44 ± 0.46 0.19
Minimum_T1 −1.84 ± 0.44 − 1.75 ± 0.42 0.22
GLNU_T1 5.24 ± 2.51 5.52 ± 2.40 0.49
Prognosis 0.64
 Disease progression 51 25  
 Non-disease progression 68 27  
  1. Treatment: A-Radiotherapy, B-Chemotherapy + Radiotherapy, C-Targeted therapy + Radiotherapy, D-Concurrent Chemoradiotherapy + Targeted Therapy, E-Chemotherapy + Targeted Therapy; * indicates statistical significant difference